Completed PHASE1 INTERVENTIONAL 3-arm NCT05976503

A Study of the Interaction of Tunodafil Hydrochloride Tablets and Alcohol

A Randomized, Blind, Placebo-controlled, Three-way Crossover Study to Evaluate the Potential Interaction of Tunodafil Hydrochloride Tablets and Alcohol in Healthy Chinese Male Participants

Sponsor: Yangtze River Pharmaceutical Group Co., Ltd.

Conditions Erectile Dysfunction

Interventions Alcohol Placebo Tunodafil Hydrochloride Tablets

Updated 4 times since 2023 Last updated: Jul 28, 2023 Started: Dec 19, 2022 Primary completion: Mar 8, 2023 Completion: Mar 21, 2023

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT05976503, this PHASE1 trial focuses on Erectile Dysfunction and remains completed. Sponsored by Yangtze River Pharmaceutical Group Co., Ltd., it has been updated 4 times since 2022, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

4 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE1
Sep 2024 — Sep 2025 [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Sep 2023 — Jul 2024 [monthly]

Completed PHASE1

First recorded

Dec 2022

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Yangtze River Pharmaceutical Group Co., Ltd.

Data source: Yangtze River Pharmaceutical Group Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Beijing, China